<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452762</url>
  </required_header>
  <id_info>
    <org_study_id>VITdAL-PICU-01</org_study_id>
    <nct_id>NCT02452762</nct_id>
  </id_info>
  <brief_title>Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial</brief_title>
  <acronym>VITdAL-PICU</acronym>
  <official_title>Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Eastern Ontario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Documented roles for vitamin D in calcium homeostasis, cardiovascular and respiratory health,&#xD;
      inflammation, innate immunity, and neuromuscular function have led to the hypothesis that&#xD;
      deficiency might represent a modifiable risk factor for outcomes in critical illness. In&#xD;
      recent years, dozens of adult studies have reported both high deficiency rates, and&#xD;
      associations between lower vitamin D levels and organ dysfunction, health resource&#xD;
      utilization, and mortality in the intensive care unit (ICU). More recently, similar&#xD;
      observations have been made in critically ill pediatric populations. The cumulative body of&#xD;
      basic science and clinical literature demonstrates that deficiency is common in critical&#xD;
      illness and rapid normalization of vitamin D status could improve clinical outcomes and/or&#xD;
      reduce health care costs. However, before conducting a phase III trial to determine whether&#xD;
      restoration of vitamin D status improves outcomes in the PICU, the appropriate dosing regimen&#xD;
      must be identified. Consequently, the investigators propose a phase II, double blind&#xD;
      randomized controlled trial to determine a loading therapy dosing regimen that can safely and&#xD;
      rapidly normalize vitamin D status in critically ill children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background &amp; Rationale: Documented roles for vitamin D in calcium homeostasis, cardiovascular&#xD;
      and respiratory health, inflammation, innate immunity, and neuromuscular function have led to&#xD;
      the hypothesis that deficiency might represent a modifiable risk factor for outcomes in&#xD;
      critical illness. In recent years, dozens of adult studies have reported both high deficiency&#xD;
      rates, and associations between lower vitamin D levels and organ dysfunction, health resource&#xD;
      utilization, and mortality in the intensive care unit (ICU). More recently, similar&#xD;
      observations have been made in critically ill pediatric populations. The cumulative body of&#xD;
      basic science and clinical literature demonstrates that deficiency is common in critical&#xD;
      illness and rapid normalization of vitamin D status could improve clinical outcomes and/or&#xD;
      reduce health care costs. However, before conducting a phase III trial to determine whether&#xD;
      restoration of vitamin D status improves outcomes in the PICU, the appropriate dosing regimen&#xD;
      must be identified. Consequently, the investigators propose a phase II, double blind&#xD;
      randomized controlled trial to determine a loading therapy dosing regimen that can safely and&#xD;
      rapidly normalize vitamin D status in critically ill children.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary Objective: Determine whether a weight-based loading protocol can rapidly normalize&#xD;
      blood vitamin D levels in critically ill children Secondary Objectives: (1) Evaluate whether&#xD;
      a weight-based loading protocol, when compared with usual care, results in a greater&#xD;
      occurrence of vitamin D related adverse events (hypercalcemia, hypercalciuria); and (2)&#xD;
      determine the barriers to and feasibility of a multicenter phase III randomized control trial&#xD;
      evaluating whether rapid vitamin D normalization improves clinical outcome and/or reduces&#xD;
      health care spending in critically ill children.&#xD;
&#xD;
      Eligibility Criteria: The inclusion criteria for this study are: (i) Admitted to ICU, (ii)&#xD;
      Corrected gestational age &gt; 37 weeks to age &lt; 18 years, (iii) Expected ICU admission in&#xD;
      excess of 48 hours and expected access for blood work at Day 7 of hospital admission, and&#xD;
      (iv) Blood 25(OH)D less than 50 nmol/L (regardless of prior approach to supplementation).&#xD;
      Exclusion criteria are: (i) Significant gastrointestinal disorder preventing enteral drug&#xD;
      administration (e.g. necrotizing enterocolitis); (ii) Hypercalcemia (excluding transient&#xD;
      abnormalities and those related to parenteral calcium administration for hypocalcemia); (iii)&#xD;
      Confirmed or suspected William's syndrome; (iv) Patient known to have nephrolithiasis or&#xD;
      Nephrocalcinosis; (v) Imminent plan for withdrawal of care or transfer to another ICU; (vi)&#xD;
      Physician refusal; (vii) Previous enrollment in the study; (viii) Patient known to have&#xD;
      granulomatous disease (tuberculosis or sarcoidosis), (ix) Severe liver dysfunction/liver&#xD;
      failure; (x) Patient know to have hypersensitivity or allergy to vitamin D or any of the&#xD;
      non-medicinal ingredients of the formulation; (xi) Patient on thiazide diuretics who is also&#xD;
      receiving regular ongoing calcium supplementation above the daily recommended intake (for&#xD;
      reasons other than hypocalcemia); (xii) Adolescent female of child-bearing age with a&#xD;
      positive serum pregnancy test; or (xiii) Patient on digoxin-therapy&#xD;
&#xD;
      Patients meeting inclusion criteria #1-3 and with no exclusion criteria will be approached&#xD;
      regarding participation. If consent is given, 25OHD will be determined and those under 50&#xD;
      nmol/L will be randomized. Participants will be stratified by age in two categories (above 30&#xD;
      days of age or below/equal to 30 days of age). Randomization/allocation concealment will be&#xD;
      performed using a web-based randomization system.&#xD;
&#xD;
      Interventions: All participants may also receive standard vitamin D dosing (e.g. 400 IU/day).&#xD;
      Sixty-seven patients will be randomized 2:1 to the intervention (Enteral loading arm)&#xD;
&#xD;
        1. Enteral loading arm: 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
&#xD;
        2. Placebo arm: For blinding purposes, this arm will receive a placebo solution&#xD;
&#xD;
      Data Collection: Blood and urine will be collected on days 0 (enrolment day), 1, 2, 3, 7,&#xD;
      hospital discharge, and after interventions or triggers known to influence vitamin D status&#xD;
      (e.g. cardiopulmonary bypass, hospital stay &gt;30 days). Information on demographics, hospital&#xD;
      course, adverse events, and health resource utilization will be entered into an electronic&#xD;
      case report form.&#xD;
&#xD;
      Sample Size: Randomization of 40 children into the loading arm will provide sufficient power&#xD;
      to estimate the proportion achieving target 25OHD with a confidence interval of Â±15%.&#xD;
      Assuming a 5% non-compliance/drop-out rate in each arm, randomization of 60 patients (total)&#xD;
      may be required to achieve the desired power. The dosing regimen for this study was changed&#xD;
      from a double dose to a single dose after the first seven patients were enrolled. As a&#xD;
      result, the sample size was increased to 67 patients. All patients (n=67) will be included in&#xD;
      the final intention to treat analysis. The 60 patients who received a single dose will be&#xD;
      included in the per protocol analysis.&#xD;
&#xD;
      Significance: Critical illness occurs in tens of thousands of children each year in North&#xD;
      America and can result in death, significant suffering, prolonged periods of rehabilitation,&#xD;
      and chronic illness. High vitamin D deficiency rates in PICUs and the recognized interaction&#xD;
      between vitamin D status and the health of multiple organ systems suggest that vitamin D&#xD;
      could represent an inexpensive, safe means of improving outcomes and reducing health care&#xD;
      spending. Unfortunately, approved daily dosing regimens require months to restore vitamin D&#xD;
      levels and there have been no studies of loading therapy in pediatric critical illness.&#xD;
      Consequently, despite significant literature suggesting vitamin D deficiency to be a&#xD;
      modifiable risk factor, there is no evidence to inform physicians on the true benefits or&#xD;
      risks of loading therapy. The proposed phase II clinical trial will determine how to provide&#xD;
      cholecalciferol loads to facilitate rapid normalization of vitamin D levels, and provide&#xD;
      initial information on toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D Status</measure>
    <time_frame>7 days</time_frame>
    <description>The percentage of critically ill children who achieve a blood 25OHD concentration above 75 nmol/L by day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Accrual Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The investigators will determine the feasibility of a subsequent multicentre phase III interventional study through an evaluation of patient accrual rate. The expected patient accrual rate is 88 patients over a 2-year period (2-5 patients per month per centre; low estimate 60 patients (0-2 per month per centre). The study will be considered feasible if the patient accrual rate is achieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Related Adverse Events</measure>
    <time_frame>On days 1, 2, 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
    <description>A measurable difference in clinically significant adverse events between the loading dose and placebo arms in unlikely in a phase II study. Therefore, the investigators will evaluate for potential toxicity using two well accepted surrogate outcome measures: (1) Hypercalcemia - The investigators will define hypercalcemia as an ionized calcium level above 1.40 mmol/L (children under 8 weeks as &gt; 1.45 mmol/l); and (2) Hypercalciuria - Hypercalciuria will be defined as an elevated calcium:creatinine ratio above age-based normal values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Axis Function - Calcium</measure>
    <time_frame>On day 0, 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
    <description>Improved signalling through the vitamin D axis will be evaluated through an evaluation of blood calcium levels (i.e. calcium metabolism). Calcium levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D Axis Function - 1,25-dihydroxyvitamin D</measure>
    <time_frame>On day 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
    <description>Improved signalling through the vitamin D axis will be evaluated through an evaluation of blood 1,25OHD levels. 1,25 levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Function - Cathelicidin</measure>
    <time_frame>On day 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
    <description>Immune function will be evaluated through an evaluation of blood cathelicidin levels. Cathelicidin levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>Enteral Loading Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Enteral Loading Arm</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (i) Admitted to ICU; (ii) Corrected gestational age &gt; 37 weeks to age &lt; 18 years; (iii)&#xD;
        Expected ICU admission in excess of 48 hours and expected access for blood work at Day 7 of&#xD;
        hospital admission; (iv) Blood 25OHD less than 50 nmol/L (regardless of prior approach to&#xD;
        supplementation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (i) Significant gastrointestinal disorder preventing enteral drug administration (e.g.&#xD;
        necrotizing enterocolitis); (ii) Hypercalcemia (excluding transient abnormalities and those&#xD;
        related to parenteral calcium administration for hypocalcemia); (iii) Confirmed or&#xD;
        suspected William's syndrome; (iv) Patient known to have nephrolithiasis or&#xD;
        Nephrocalcinosis; (v) Imminent plan for withdrawal of care or transfer to another ICU; (vi)&#xD;
        Physician refusal; (vii) Previous enrollment in the study; (viii) Patient known to have&#xD;
        granulomatous disease (tuberculosis or sarcoidosis), (ix) Severe liver dysfunction/liver&#xD;
        failure; (x) Patient know to have hypersensitivity or allergy to vitamin D or any of the&#xD;
        non-medicinal ingredients of the formulation; (xi) Patient on thiazide diuretics who is&#xD;
        also receiving regular ongoing calcium supplementation above the daily recommended intake&#xD;
        (for reasons other than hypocalcemia); (xii) Adolescent female of child-bearing age with a&#xD;
        positive serum pregnancy test; or (xiii) Patient on digoxin-therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D McNally</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Eastern Ontario</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Menon Kusum</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Eastern Ontario</affiliation>
  </overall_official>
  <overall_official>
    <last_name>McIntyre Lauralyn</last_name>
    <role>Study Chair</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fergusson Dean</last_name>
    <role>Study Chair</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amrein Karin</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Critical Care, Department of Pediatrics, Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 3T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Guillermo Grant Benavente</name>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2021</results_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Eastern Ontario</investigator_affiliation>
    <investigator_full_name>James Dayre McNally</investigator_full_name>
    <investigator_title>Pediatric Intensivist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT02452762/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible participants were recruited from participating PICUs and one Neonatal Intensive Care Unit (NICU) between January 2016 to August 2017</recruitment_details>
      <pre_assignment_details>This study did not involve a wash out or run-in period. The trial intervention initially involved two doses of study drug (placebo or cholecalciferol): i) At time of enrollment, and i) a day 3 dose dependent on the 25(OH)D concentration achieved. However, after randomization of the first 12 patients the intervention was adjusted to a single-dose protocol. Seven children who were enrolled under the two-dose protocol received &gt;1 loading dose of cholecalciferol and were excluded from the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enteral Loading Arm</title>
          <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Received &gt;1 loading dose of cholecalciferol and analyzed separately</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enteral Loading Arm</title>
          <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.4" lower_limit="2.1" upper_limit="86.6"/>
                    <measurement group_id="B2" value="11.8" lower_limit="2.1" upper_limit="87.9"/>
                    <measurement group_id="B3" value="12.8" lower_limit="2.0" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mechanical ventilation required, frequency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Received catecholamines, frequency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ICU type, frequency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Pediatric Intensive Care Unit</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neonatal Intensive Care Unit</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ICU Admission season, frequency</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Fall</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Winter</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Spring</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Summer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vitamin D Status</title>
        <description>The percentage of critically ill children who achieve a blood 25OHD concentration above 75 nmol/L by day 7</description>
        <time_frame>7 days</time_frame>
        <population>A blood sample for the primary outcome analysis was available for 56 participants, 38 in the treatment arm and 18 in the placebo arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Enteral Loading Arm</title>
            <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D Status</title>
          <description>The percentage of critically ill children who achieve a blood 25OHD concentration above 75 nmol/L by day 7</description>
          <population>A blood sample for the primary outcome analysis was available for 56 participants, 38 in the treatment arm and 18 in the placebo arm.</population>
          <units>Percentage of participants in study arm</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="66.6" upper_limit="90.8"/>
                    <measurement group_id="O2" value="5.6" lower_limit="1.0" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Accrual Rate</title>
        <description>The investigators will determine the feasibility of a subsequent multicentre phase III interventional study through an evaluation of patient accrual rate. The expected patient accrual rate is 88 patients over a 2-year period (2-5 patients per month per centre; low estimate 60 patients (0-2 per month per centre). The study will be considered feasible if the patient accrual rate is achieved</description>
        <time_frame>2 years</time_frame>
        <population>The number of patients per enrolled per month per centre</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Cohort</title>
            <description>Includes all randomized participants (both the Enteral Loading Arm and the Placebo Arm)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Accrual Rate</title>
          <description>The investigators will determine the feasibility of a subsequent multicentre phase III interventional study through an evaluation of patient accrual rate. The expected patient accrual rate is 88 patients over a 2-year period (2-5 patients per month per centre; low estimate 60 patients (0-2 per month per centre). The study will be considered feasible if the patient accrual rate is achieved</description>
          <population>The number of patients per enrolled per month per centre</population>
          <units>Number of patients enrolled per month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vitamin D Related Adverse Events</title>
        <description>A measurable difference in clinically significant adverse events between the loading dose and placebo arms in unlikely in a phase II study. Therefore, the investigators will evaluate for potential toxicity using two well accepted surrogate outcome measures: (1) Hypercalcemia - The investigators will define hypercalcemia as an ionized calcium level above 1.40 mmol/L (children under 8 weeks as &gt; 1.45 mmol/l); and (2) Hypercalciuria - Hypercalciuria will be defined as an elevated calcium:creatinine ratio above age-based normal values</description>
        <time_frame>On days 1, 2, 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Loading Arm</title>
            <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D Related Adverse Events</title>
          <description>A measurable difference in clinically significant adverse events between the loading dose and placebo arms in unlikely in a phase II study. Therefore, the investigators will evaluate for potential toxicity using two well accepted surrogate outcome measures: (1) Hypercalcemia - The investigators will define hypercalcemia as an ionized calcium level above 1.40 mmol/L (children under 8 weeks as &gt; 1.45 mmol/l); and (2) Hypercalciuria - Hypercalciuria will be defined as an elevated calcium:creatinine ratio above age-based normal values</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hypercalcemia</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hypdercalciuria</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Hypercalcemia or Hypercaliuria</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vitamin D Axis Function - Calcium</title>
        <description>Improved signalling through the vitamin D axis will be evaluated through an evaluation of blood calcium levels (i.e. calcium metabolism). Calcium levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
        <time_frame>On day 0, 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enteral Loading Arm</title>
            <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D Axis Function - Calcium</title>
          <description>Improved signalling through the vitamin D axis will be evaluated through an evaluation of blood calcium levels (i.e. calcium metabolism). Calcium levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
          <units>mmol/mmol</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 - Lowest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.13" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.18" lower_limit="1.14" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - Highest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="1.17" upper_limit="1.28"/>
                    <measurement group_id="O2" value="1.21" lower_limit="1.17" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Lowest ionized calcium concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="1.06" upper_limit="1.26"/>
                    <measurement group_id="O2" value="1.12" lower_limit="1.09" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Highest ionized calcium concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="1.15" upper_limit="1.29"/>
                    <measurement group_id="O2" value="1.27" lower_limit="1.14" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Lowest ionized calcium concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.12" upper_limit="1.23"/>
                    <measurement group_id="O2" value="1.17" lower_limit="1.10" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Highest ionized calcium concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="1.18" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.18" lower_limit="1.17" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital discharge - Lowest ionized calcium concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="1.18" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.20" lower_limit="1.15" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital discharge - Highest ionized calcium concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.18" upper_limit="1.32"/>
                    <measurement group_id="O2" value="1.24" lower_limit="1.18" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vitamin D Axis Function - 1,25-dihydroxyvitamin D</title>
        <description>Improved signalling through the vitamin D axis will be evaluated through an evaluation of blood 1,25OHD levels. 1,25 levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
        <time_frame>On day 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
        <population>Data was not collected for this outcome. Due to insufficient funding and insufficient blood sample volume after analysis of the primary outcome, we were unable to complete this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enteral Loading Arm</title>
            <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin D Axis Function - 1,25-dihydroxyvitamin D</title>
          <description>Improved signalling through the vitamin D axis will be evaluated through an evaluation of blood 1,25OHD levels. 1,25 levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
          <population>Data was not collected for this outcome. Due to insufficient funding and insufficient blood sample volume after analysis of the primary outcome, we were unable to complete this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Function - Cathelicidin</title>
        <description>Immune function will be evaluated through an evaluation of blood cathelicidin levels. Cathelicidin levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
        <time_frame>On day 3, 7, hospital discharge (expected average of 2 weeks)</time_frame>
        <population>Data was not collected for this outcome. Due to insufficient funding and insufficient blood sample volume after analysis of the primary outcome, we were unable to complete this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Enteral Loading Arm</title>
            <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Function - Cathelicidin</title>
          <description>Immune function will be evaluated through an evaluation of blood cathelicidin levels. Cathelicidin levels will be reported as median plus interquartile range and will be compared between the 2 study groups.</description>
          <population>Data was not collected for this outcome. Due to insufficient funding and insufficient blood sample volume after analysis of the primary outcome, we were unable to complete this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for adverse events from the time of study enrollment (administration of the study drug) until 90 days following enrollment.</time_frame>
      <desc>Ionized calcium levels and urine calcium:creatinine ratios from study samples were monitored in real time by the site investigator for hypercalcemia (study days 1, 2, 3, 7 and at hospital discharge) and hypercalciuria (study day 3, 7 and at hospital discharge). Additionally, the 25(OH)D level at Day 7/discharge was reviewed by the study nephrologist</desc>
      <group_list>
        <group group_id="E1">
          <title>Enteral Loading Arm</title>
          <description>Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)&#xD;
Vitamin D3</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent hypercalcemia</sub_title>
                <description>Ionized blood calcium &gt;1.4 mmol/mmol in children 2 months and older, or an ionized blood calcium &gt;1.45 mmol/mmol in children younger than 2 months</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Persistent hypercalciuria</sub_title>
                <description>Calcium:creatinine ratio above age-established thresholds in two, sequential post-intervention urine samples</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Nephrocalcinosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Nephrocalcinosis on abdominal ultrasound</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Dayre McNally, Principal Investigator and Pediatric Intensivist</name_or_title>
      <organization>Children's Hospital of Eastern Ontario</organization>
      <phone>613-737-7600 ext 3553</phone>
      <email>dmcnally@cheo.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

